PUBLIC COMPANY
save$VXRTVaxart, Inc.
$VXRT0.4000-1.84%South San Francisco, CA, USupdated 13d ago
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc.
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Preclinical1Phase 13Phase 2
Phase 2
COVID-19 (S Protein)
Coronavirus Disease 2019 (COVID-19)
Phase 2Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Norovirus Infections
Phase 2VXAG-1.1NN
Norovirus Infections
Phase 1norovirus [strain GI.1] vaccine
Norovirus Infections
PreclinicalVXAHPV-16.1
Human Papillomavirus (HPV) Associated Cancer
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that